TNET Stock Analysis: TriNet | NYSE
Staffing & Employment Services | NYSE, USA | Market Cap: 2.517m USD | 12M Return: -5.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 17.4M
EPS Trend: -88.6%
Qual. Beats: 1
Rev. Trend: 58.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
TriNet Group, Inc. (NYSE: TNET) is a U.S.-based provider of human capital management services focused on small and medium-sized businesses. Its offerings span payroll processing, tax administration, employee benefits (health insurance and retirement plans), workers compensation, HR compliance, and an online technology platform for managing HR transactions and workforce analytics. The company serves clients across technology, professional services, financial services, life sciences, and not-for-profit industries, selling primarily through a direct sales force. Founded in 1988 and headquartered in Dublin, California, TriNet has been publicly traded since its 2014 IPO.
The company operates as a Professional Employer Organization (PEO), a business model in which the PEO enters into a co-employment relationship with client companies, sharing employer responsibilities for the clients workforce. This model allows SMBs to outsource back-office HR functions and access employee benefits typically available only to larger employers. TriNet competes within the GICS Human Resource & Employment Services sub-industry alongside other major PEOs such as Insperity, ADP TotalSource, and Paychex.
- Worksite employee growth drives recurring HR services revenue
- Health insurance claims pressure gross margins on benefits pass-through
- SMB hiring slowdown reduces payroll processing volume
| Net Income: 159.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -1.93 > 1.0 |
| NWC/Revenue: 5.22% < 20% (prev 4.14%; Δ 1.08% < -1%) |
| CFO/TA 0.10 > 3% & CFO 357.0m > Net Income 159.0m |
| Net Debt (656.0m) to EBITDA (379.0m): 1.73 < 3 |
| Current Ratio: 1.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.0m) vs 12m ago -4.08% < -2% |
| Gross Margin: 17.68% > 18% (prev 19.03%; Δ -1.35% > 0.5%) |
| Asset Turnover: 137.4% > 50% (prev 135.0%; Δ 2.38% > 0%) |
| Interest Coverage Ratio: 5.09 > 6 (EBIT TTM 280.0m / Interest Expense TTM 55.0m) |
| A: 0.08 (Total Current Assets 2.48b - Total Current Liabilities 2.23b) / Total Assets 3.42b |
| B: -0.31 (Retained Earnings -1.07b / Total Assets 3.42b) |
| C: 0.08 (EBIT TTM 280.0m / Avg Total Assets 3.60b) |
| D: 0.02 (Book Value of Equity 83.0m / Total Liabilities 3.34b) |
| Altman-Z'' = 0.03 = B |
| DSRI: 0.95 (Receivables 458.0m/499.0m, Revenue 4.94b/5.10b) |
| GMI: 1.08 (GM 19.03% / 17.68%) |
| AQI: 1.09 (AQ_t 0.26 / AQ_t-1 0.23) |
| SGI: 0.97 (Revenue 4.94b / 5.10b) |
| TATA: -0.06 (NI 159.0m - CFO 357.0m) / TA 3.42b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of July 17, 2026, the stock is trading at USD 60.47 with a total of 459,544 shares traded. Over the past week, the price has changed by +10.37%, over one month by +30.64%, over three months by +56.57% and over the past year by -5.77%.
Current recommended Stop Loss: 56.40 (which is 6.7% or 1.9 ATR below the current price).
TriNet has received a consensus analysts rating of 3.43. Therefore, it is recommended to hold TNET.
- StrongBuy: 2
- Buy: 0
- Hold: 4
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 53.8 | -11% |
P/E Trailing = 16.2101
P/E Forward = 7.9239
P/S = 0.5157
P/B = 30.4452
P/EG = 7.216
Revenue TTM = 4.94b USD
EBIT TTM = 280.0m USD
EBITDA TTM = 379.0m USD
Long Term Debt = 896.0m USD (from longTermDebt, last quarter)
Short Term Debt = 11.0m USD (from shortTermDebt, last quarter)
Debt = 996.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 50.0m
Net Debt = 656.0m USD (calculated: Debt 996.0m - CCE 340.0m)
Enterprise Value = 3.17b USD (2.52b + Debt 996.0m - CCE 340.0m)
Interest Coverage Ratio = 5.09 (Ebit TTM 280.0m / Interest Expense TTM 55.0m)
EV/FCF = 9.62x (Enterprise Value 3.17b / FCF TTM 330.0m)
FCF Yield = 10.40% (FCF TTM 330.0m / Enterprise Value 3.17b)
FCF Margin = 6.67% (FCF TTM 330.0m / Revenue TTM 4.94b)
Net Margin = 3.22% (Net Income TTM 159.0m / Revenue TTM 4.94b)
Gross Margin = 17.68% ((Revenue TTM 4.94b - Cost of Revenue TTM 4.07b) / Revenue TTM)
Gross Margin QoQ = 23.08% (prev 12.42%)
Tobins Q-Ratio = 0.93 (Enterprise Value 3.17b / Total Assets 3.42b)
Interest Expense / Debt = 5.52% (Interest Expense 55.0m / Debt 996.0m)
Taxrate = 29.33% (66.0m / 225.0m)
NOPAT = 197.9m (EBIT 280.0m * (1 - 29.33%))
Current Ratio = 1.12 (Total Current Assets 2.48b / Total Current Liabilities 2.23b)
Debt / Equity = 12.0 (Debt 996.0m / totalStockholderEquity, last quarter 83.0m)
Debt / EBITDA = 1.73 (Net Debt 656.0m / EBITDA 379.0m)
Debt / FCF = 1.99 (Net Debt 656.0m / FCF TTM 330.0m)
Total Stockholder Equity = 88.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.42% (Net Income 159.0m / Total Assets 3.42b)
RoE = 179.7% (Net Income TTM 159.0m / Total Stockholder Equity 88.5m)
RoCE = 28.44% (EBIT 280.0m / Capital Employed (Equity 88.5m + L.T.Debt 896.0m))
RoIC = 20.66% (NOPAT 197.9m / Invested Capital 957.8m)
WACC = 6.05% (E(2.52b)/V(3.51b) * Re(6.90%) + D(996.0m)/V(3.51b) * Rd(5.52%) * (1-Tc(0.29)))
Discount Rate = 6.90% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.53 | Cagr: -3.57%
[DCF] Terminal Value 73.10% ; FCFF base≈372.8m ; Y1≈326.9m ; Y5≈264.1m
[DCF] Fair Price = 78.00 (EV 4.24b - Net Debt 656.0m = Equity 3.58b / Shares 45.9m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -88.61 | EPS CAGR: -17.86% | SUE: 2.03 | # QB: 1
Revenue Correlation: 58.69 | Revenue CAGR: 0.97% | SUE: 0.56 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.93 | Chg30d=+0.15% | Revisions=+25% | Analysts=7
EPS next Quarter (2026-09-30): EPS=0.81 | Chg30d=+0.36% | Revisions=+25% | Analysts=7
EPS current Year (2026-12-31): EPS=4.54 | Chg30d=+0.19% | Revisions=+25% | GrowthEPS=-4.0% | GrowthRev=-3.6%
EPS next Year (2027-12-31): EPS=4.85 | Chg30d=+0.27% | Revisions=+25% | GrowthEPS=+6.7% | GrowthRev=+3.8%
[Analyst] Revisions Ratio: +57% (up=4, down=0)